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ABSTRACT
The paper reports the screening results of two metal-based antineoplastic drugs with mutagenic
potential, such as Romcis (trademark of Cisplatinum, produced in Romania) and diphenylantimony(lll)
diisopropyldithiophosphate (PADTF). Their effects were compared with those induced by
Cyclophosphamide. Two mutagenicity tests, the SOS Chromotest and cytogenetic analysis were
applied. The tests were carded out with or without metabolic activation (addition of Sg-mix), either in E.
coli PQ 37 cultures, using four doses (0.3, 3, 30 and 300 pmol compound/assay) for the SOS
Chromotest or in leukocyte cultures using 0.3 mM from each compound, for cytogenetics. The dose-
response relationships and SOSIP values revealed an indirect mutagenic potential for
Cyclophosphamide, amplified byS mix in bacterial cultures and an antiproliferative clastogenic effect
on lymphocytes. For Romcis and diphenylantimony(lll) diisopropyldithiophosphate, a significant positive
response by SOS Chromotest was recorded, which correlated with increased frequencies of
chromosomal aberrations.
INTRODUCTION
The selection of the most appropiate tests for" the control of genotoxicity induced by physical or
chemical agents, including drugs is still a subject of debate. A unique strategy is not yet established,
although a lot of short-term or long-term test batteries have been developed.
1
A simple sequential testing strategy recommends as a first step, in vitro tests like Salmonella
Assay (Ames test) and cytogenetic analysis on lymphocytes or CHO cells.
3 These tests proved to be
good predictive tools for estimating the carcinogenic potential, by the association of a bacterial assay
with the chromosomal aberrations test, which detects complementary cdtical genetic end-points.
A bacterial test, called the SOS Chromotest, was recently described and proved to be a very
convenient short-term test for the screening of genotoxic agents,s’s This test quantifies the SOS-
response of a particular strain, E. coli PQ 37, to DNA-damaging agents by the activation of theVol. 3, No. 2, 1996 Genotoxicity ofSome Metal-BasedAntineoplastics
structural lac Z gene functions (for 13-galactosidase synthesis) which is fused with the sfiA control
gene.7’8 The 13-galactosidase and alkaline phosphatase activities are quantitative markers of
genotoxicity, easily determined in a very short time. A validation of this test has been reported for
hundreds of chemicals.6’9 The good correlation obtained with the Salmonella test suggests that the
SOS Chromotest is a complementary screening assay in a short-term battery for detecting genotoxins.
The International Commission for Protection against Environmental Mutagens and
Carcinogens recommends the use of cytogenetic analysis as a screening test for monitoring
mutagenicity. In vitro cytogenetics can utilise animal or human lymphocytes for evaluating the
chromosomal aberrations as an end-point of mutagenicity.
The experimental data concerning the inhibitory effects of platinum coordination compounds
on E. coli division rapidly led to the testing of their potential in cancer chemotherapy. 12’13 Their
mechanisms of action, common to other metal coordination compounds are now elucidated
146 and
some of them are used as cytostatics.
7
Our interest has been focused on the screening of new chemicals or antineoplastic drugs with
mutagenic potential, using the most relevant "in vitro" short-term tests. In this context, we were
interested to compare two tests one performed with a bacterial system and the other one with
mammalian cells for genotoxic potential of some antineoplastics.
Cyclophosphamide, a well known antineoplastic, revealed conflicting results by different
genotoxty tests.
6 The possible use of organometallic compounds as antitumor agentsa3’18’9 stimulated
our interest to investigate their mutagenic potential. Recently, the genotoxicity of 14 organotin
compounds (butyltins, phenyltins and methyltins) established using the SOS Chromotest and the rec-
assay tests was reported.
2
We report here the results obtained using three antineoplastics: Cyclophosphamide, Romcis
(Romanian trademark of Cisplatinum) and diphenylantimony(lll) diisopropyldithiophosphate, which
were comparatively investigated by SOS Chromotest, with or without metabolic activation and by
cytogenetic analysis, in blood lymphocytes. Their genotoxic potential is discussed.
MATERIALS AND METHODS
Tested compounds. Two Cyclophosphamide trademarks were tested: the first one Romanian
Ciclofosfamida (CFr), produced by Drugs Entreprise, Bucharest, Romania and the second one,
German Cyclophosphamide (CFg) produced by VEB JenaPharm, Jena, Germany. Two metal
compounds were comparatively investigated: Romcis (RC), produced by the Institute of Chemistnj,
Timisoara, Romania, and a new organometallic compound possessing antitumor activity,
diphenylantimony(lll) diisopropyldithiophosphate (abbreviated in the subsequent discussion as
PADTF).’19
The metal compounds, RC and PADTF were first dissolved in DMSO at OM and afterwards
three successive dilutions to 10, 10 and IOM were applied. The same concentrations were made
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for CFr and CFg, using distilled water as solvent. Considering the dilution factor in the cell suspensions
(1:30), the effective final concentrations in bacterial media were 3xl0"M, 3x10TM, 3xl0M, 3xl0M,
respectively and 3xl0M in the lymphocyte suspension.
Bacterial strain, buffers and equipment forSOS Chromotest. The experiments were performed
using the standard tester strain, E. coil PQ37, kindly offered by Prof. M.Hofnung, Institute Pasteur,
Pads, together with other chemical reagents needed to perform the SOS Chromotest.
Tris(hydroxymethyl)aminomethane (Tris), sodium dodecylsulphate (SDS) and dimethyl-
sulphoxide (DMSO) were Merck products. Glucose-6-phosphate (G6P) and nicotinamide adenine
dinucleotide phosphate (NADP) were from Sigma. The buffers, media (La, L) and other reagents,
including the activation mixture $9-mix were made as previously describeds the liver $9 microsome
fraction was prepared from Aroclor 1254-treated rats and the composition of S-mix was the following
10 % $9, 61% L medium, 25% Tris buffer 0.4 M pH 7.4, 1.5% NADP 0.1 M, 0.5% G6P M, 2% salt
solution 1.65 M KCI + 0.4 M MgCI2. 6H20).
Cultures and testing conditions for the SOS Chromotest. The assays were performed starting
from an overnight culture of E. coli PQ 37 at 37C, obtained by the dilution of 0.05 ml of frozen culture
of tester strain in 5 ml of La medium. A volume of 0.5 ml of overnight culture was added to 20 ml La
medium and the mixture was maintained at 37C in a gyratory incubator. The cell suspension was
checked for its density, which reached a value of 5x107 cells/ml after 2.5 hrs. Then, 5 ml of culture
were diluted, either in 5 ml of fresh L medium for the assays without activation or in 5 ml of S-mix, for
metabolic activation. Fractions containing 0.6 ml were distributed in disposable stoppered glass test
tubes containing 20 ml from each dilution, corresponding to the following doses per assay: 0.3, 3.0, 30
and 300 pmol. The mixtures were incubated with shaking for 2 hrs at 37C and then each suspension
was equally divided into two tubes, the first one for the 13-galactosidase (13-Gal) assay and
the second one for the alkaline phosphatase (P-ase)assay. The assays were performed
concomitantly: for 13 -galactosidase, 0.3 ml suspension was added to 2.5 ml B buffer while for alkaline
phosphatase to 2.5 ml P buffer. Both mixtures were developed as previously described8, the
absorbances were read at 420 nm (A420) against a control (C) containing 0.3 ml L. medium or S-mix
instead of cell suspensions.
6
The enzyme activities and the R ratios were calculated from simplified formulas
Enzyme units = 1000 x A20 / t where t length of incubation (min)
R 13-Gal units / P-ase units
The induction factor (I) represents the ratio between R values registered at different
concentrations to the R values registered for control. The SOS-inducing potency (SOSIP) is the slope
of the linear region of the dose-response curves and represents the induction factor per nanomole of
compound tested in the absence or presence of activation mixture $9 -mix.
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Cytogenetic analysis. Bovine blood lymphocytes were separated and cultured in RPMI-1640
medium containing 15% FCS, at a density of 2x 106 cells/ml and supplemented with 20 IJg/ml PHAM.
All the tested compounds were added to the cell suspension at the begining of 72-h cultures,
using for each one the same concentration, 3xl0M, corresponding to the highest concentration used
in the SOS Chromotest. Control cultures (C) containing the same volume of DMSO and also negative
control (NC) cultures, without DMSO, were concomitantly treated. All cultures were harvested after 72
hrs and the chromosome preparations were made according to standard procedures. We analysed 100
Giemsa-stained metaphases per culture and the most important chromatid or chromosome aberrations
(breaks, exchanges) were counted and classified.
RESULTS AND DISCUSSION
SOS Chromotest dose-response relationships
Tables and II represents the enzyme activities expressed as I-Gal and P-ase units, as well
the R and I values determined for all compounds in the absence or in the presence of Sg-mix. Using the
same doses for each compound, from 0.3 to 300 pmol per assay, different responses were registered
for cyclophosphamides (CFr and CFg) and metal compounds (RC and PADTF). If the enzyme
activities were almost constant for increasing doses of CF, a gradual increase of activities was
observed for RC and PADTF.
Table I. SOS Chromotest results: enzyme activities, R and values in the absence of
activation (- Sg-mix).
Compound
(pmollassay)
13-Gal units P-ase units R I
Control 2.3 20.6 0.113 1
CFr/CFg
0.3 11.1/11.4 29.2/28.6 0.38/0.39 3.4/3.5
3.0 12.1/12.3 28.8/27.7 0.42/0.44 3.7/3.9
30.0 12.2/12.2 32.2/30.8 0.38/0.39 3.3/3.5
300.0 12.2/12.4 36.4/32.5 0.33/0.38 2.9/3.4
RC
0.3 11.1 20.4 0.54 4.82
3.0 12.2 21.2 0.57 5.08
30.0 13.1 20.8 0.63 5.56
300.0 18.3 22.4 0.82 7.23
PADTF
0.3 11.7 28.4 0.41 3.63
3.0 14.9 28.4 0.52 4.63
30.0 22.1 38.6 0.57 5.06
300.0 42.1 46.5 0.90 8.0
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In the absence of activation mixture, at the highest dose, the induction factor (I) had values of
2.9- 3.3 for CF and 7.23 or 7.99 for RC and PADTF, respectively. With metabolic activation, these
values increased for all compounds but significantly (p < 0.005) only for RC and PADTF.
The dose-response curves obtained from these data were linear, almost dose-independent for
CF or had a slight increasing slope for 13-Galactosidase (13-Gal) activity beginning with 3 pmol/assay for
RC and PADTF, while the alkaline phosphatase (P-ase) activity was constant. The presence of S9-mix
induced in all cases increases of 13-Gal activity, slight decreases of P-ase activity and higher induction
factors, especially for RC and PADTF.
Table II. SOS Chromotest results: enzyme activities, R and values in the presence of
activation + S9-mix).
Compound I-Gal units P-ase units R I
(pmollassay)
Control 1.1 10.3 0.11 1
CFr/CFg
0.3 11.1111.6 20.2/20.6 0.55/0.56 4.9/5.0
3.0 12.1/12.4 20.4/21.2 0.59/0.58 5.3/5.2
30.0 12.4/12.6 21.1/21.8 0.59/0.58 5.3/5.2
300.0 12.6112.6 21.4/21.8 0.59/0.58 5.3/5.2
RC
0.3 12.3 16.2 0.76 6.8
3.0 14.6 17.4 0.84 7.5
30.0 26.8 17.6 1.52 13.7
300.0 32.2 18.2 1.77 15.9
PADTF
0.3 12.1 22.4 0.53 4.8
3.0 26.2 26.1 1.02 9.0
30.0 38.2 28.1 1.35 12.2
300.0 62.1 30.4 2.03 18.3
SOS Chromotest the induction factors and SOSIP
Figure represents the induction kinetics for all tested compounds. For both CF products the I
values were almost independent of the dose and of the addition of Sg-mix. For RC and PADTF, the I
values had a linear increasing kinetic, stimulated by the addition of Sg-mix. From the slopes of I =
f(dose), the SOSIP values were calculated and compared for all tested compounds, in the presence or
absence of Sg-mix (Table III). These values are larger in the presence of Sg-mix than in its absence
especially for RC and PADTF :in the absence of S-mix SOSIP values were 8 and 14.5 and by S-mix
addition, these values reached at 30.4 and 44.9, respectively. These values reveal for RC and PADTF
95Vol. 3, No. 2, 1996 Genotoxicity ofSome Metal-BasedAntineoplastics
-a significant mutagenic potential, amplified by metabolic activation and a slight genotoxicity for both
CF products.
Table III. SOS-inducing potency (SOSIP) of four antineoplastics tested in the absence or
presence of activation mixture.
Compound S O S P (]/nmol)
Sg-mix
S 0 S P (]/nmol)
+ S9-rnix
CFr
CFg
RC
PADTF
0 1.1
0 0.4
8 30.4
14.5 44.9
CFr
CFg
RC(1}
x PADTF (2)
pmd compocnd assay
Figure 1. Induction kinetics (dose-response slopes) registered for CFr, CFg, RC and PADTF
treatments with (solid symbols and lines) or withoutS -mix open symbols with
dashed lines).
Chromosomal analysis
Table IV contains the mean values of mitotic index (MI) and the frequencies of chromatid and
chromosome aberrations (breaks and exchanges), expressed per 100 metaphases examined. A
general decrease of MI for expedmentals compared to controls was recorded, especially for RC and
PADTF. A similar observation was made for aberrations, which had higher frequencies for RC and
PADTF treatments, especially at chromatid level (breaks and exchanges). Figure 2 shows two
metaphases containing chromatidic breaks and exchanges after the treatment with RC and PADTF.
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Table IV. Chromosomal analysis of lymphocytes treated with antineoplastics: mean values of
mitotic index (MI) and frequencies of lymphocyte chromatid/chromosomal.
abberations (expressed per 100 cells scored on slides). Abbreviations B- breaks;
E- exchanges.
Compound MI Chromatid abb. Chromosome Total abb.
(%) BIE abb, (%)
BIE
Control 6.5 210 110 3
CFr 4.6 111 110 3
CFg 4.5 112 110 4
RC 2.5 312 211 8
PADTF 1.5 3/3 211 9
Figure 2.
(a) (b)
Two metaphases showing aberrations breaks and exchanges, see arrows),
identified after the treatment with RC (a) and PADTF (b), respectively.
The cytogenetic analysis shows similar differences between the effects of CF products and RC
or PADTF. The lymphocyte mitotic index was gradually inhibited from CF (4.5-4.6) to RC (2.5) and
PADTF (1.5), while the frequency of aberrations was gradually increased in the same order (PADTF >
RC > CFr CFg) (Table IV). These results suggest a significant clastogenic potential for RC and
PADTF and a questionable effect for CF.
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An important aspect for mutagen screening is the analysis of data and legislative guidelines.
Different criteda
6, 21 are used for a correct evaluation of SOS Chromotest data but two factors are
considered as obligatory for a positive response an increase of at least 50% for the induction factor
and an evident dose-response relationships.
In this respect, we compared our results with cumulative reviews on the mutagenic potential of
the tested compounds. For Cyclophosphamide, conflicting responses were reported by SOS
Chromotest, Mutatest (Ames test),4’6 by Micronucleus test22’23 and carcinogenicity in rodents.’ In
bacterial systems, the SOS-response was negative, the Mutatest was positive while in mammals the
response was generally positive1. For platinum derivatives the mutagenic potential against E. coli is
known since its first evaluation. Positive responses were obtained using also the Salmonella test,
16 the
SOS Chromotest
6 and by cytogenetic analysis on human lymphocytes.4’22’2
Among antimony-containing derivatives, only antimony sodium tartrate was mutagenic to
lymphocytes Recently
2 some butyltin oxides and chlorides showed high SOS-inducing factors (3.2
to 5.8). Ghosh et al.2’25 reported increases in micronuclei and chromosomal aberrations induced by
trimethyltin chlodde in human lymphocytes. No data about organoantimony compounds were so far
reported.
Our results demonstrate similar response for both Cyclophosphamide products, L e. a positive
one considering the induction factors but showing weak SOS-inducing potential, with equivocal dose-
response relationships. This effect was amplified by metabolic activation, thus confirming the indirect
mutagenic potential of Cyclophosphamide. The cytogenetic analysis revealed a moderate
antiproliferative and clastogenic effect on lymphocytes, although no quantitative limits for clastogenicity
are actually established.
For Romcis and PADTF, intense positive responses were recorded, with significant high
values of induction factors, dose-dependence and a greater effect by activation with Sg-mix. The dose-
response curves had linear increasing slopes which correlate with high SOS-inducing potency. The
cytogenetic analysis confirmed their genotoxic potential by increased antiproliferative and chromosomal
aberration potency. The magnitude of these effects was greater than for Cyclophosphamides.
Further investigations are in progress, in order to establish the dose-response relationships for
a wider concentration range and by complementary mutagenicity tests like the micronucleus test,
sister-chromatid exchange. These supplementary investigations could allow a better discrimination
among real and false responses and to check the reproducibility of the present results.
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